<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131648</url>
  </required_header>
  <id_info>
    <org_study_id>LP0162-1325</org_study_id>
    <secondary_id>2016-004200-65</secondary_id>
    <nct_id>NCT03131648</nct_id>
  </id_info>
  <brief_title>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)</brief_title>
  <acronym>ECZTRA 1</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe&#xD;
      atopic dermatitis (AD).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health&#xD;
      related quality of life compared with placebo.&#xD;
&#xD;
      Maintenance objective:&#xD;
&#xD;
      To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared&#xD;
      to placebo for subjects achieving clinical response at Week 16.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects found eligible following the screening period were randomized 3:1 to initial&#xD;
      treatment with tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Randomization was&#xD;
      stratified by region (North America, Europe, and Japan) and disease severity (Investigator's&#xD;
      Global Assessment [IGA] 3 or 4).&#xD;
&#xD;
      Subjects achieving a clinical response at Week 16 (defined as IGA of 0 or 1 on a 5-point&#xD;
      scale ranging from 0 [clear] to 4 [severe], or at least 75% reduction in Eczema Area and&#xD;
      Severity Index [EASI] score from baseline [EASI75]) continued into maintenance treatment that&#xD;
      continued until Week 52.&#xD;
&#xD;
      Subjects randomized to tralokinumab in the initial treatment period and who achieved a&#xD;
      clinical response at Week 16 (defined by IGA 0 or 1, or EASI75) were re-randomized 2:2:1 to&#xD;
      one of the following Q2W maintenance regimens stratified by region (North America, Europe,&#xD;
      and Japan) and IGA response at Week 16 (IGA 0/1 or IGA &gt;1):&#xD;
&#xD;
        -  Tralokinumab 300 mg Q2W.&#xD;
&#xD;
        -  Tralokinumab 300 mg Q4W (alternating dose administrations tralokinumab 300 mg and&#xD;
           placebo).&#xD;
&#xD;
        -  Placebo (Subjects randomized to placebo in the initial treatment period who achieved a&#xD;
           clinical response at Week 16 [defined by IGA 0 or 1, or EASI75] continued to receive&#xD;
           placebo Q2W in the maintenance treatment period).&#xD;
&#xD;
      Subjects not achieving a clinical response at Week 16 as well as those who met the criteria&#xD;
      listed below during maintenance treatment were transferred to open-label tralokinumab 300 mg&#xD;
      Q2W treatment with optional use of topical corticosteroid (TCS) up to Week 52.&#xD;
&#xD;
      Transfer to open-label treatment during maintenance:&#xD;
&#xD;
      Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieved EASI75 over at least a&#xD;
      4-week period (i.e. over 3 consecutive visits).&#xD;
&#xD;
      Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieved EASI75 over at least a&#xD;
      4-week period (i.e. over 3 consecutive visits).&#xD;
&#xD;
      Subjects with IGA &gt;1 at Week 16: not achieved EASI75 over at least a 4-week period (i.e. over&#xD;
      3 consecutive visits).&#xD;
&#xD;
      Subjects transferring to open-label treatment had the option to self-administer tralokinumab&#xD;
      in their home after adequate training (at 3 dosing visits in the open-label period after&#xD;
      additional consent has been obtained) by site staff at the investigator's discretion.&#xD;
&#xD;
      After completion of the maintenance treatment period (or open-label treatment), all subjects,&#xD;
      except for those who entered the open-label long-term extension trial, continued in a 14-week&#xD;
      off-treatment follow-up period for the assessment of safety and anti-drug antibody (ADA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of the IMPs will contain no evidence of their identity.&#xD;
Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded HCP at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ‚ÅÑnot relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16</measure>
    <time_frame>At Week 52</time_frame>
    <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16</measure>
    <time_frame>At Week 52</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Anti-drug Antibodies</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with a higher values indicating a more extensive and/or severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average)</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Worst Daily Pruritus NRS (Weekly Average) ‚â•3 From Baseline to Week 16</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ‚â•4 Points Among Subjects With Baseline DLQI ‚â•4</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">802</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Initial treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 0 to Week 16:&#xD;
Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial treatment period - Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 0 to Week 16:&#xD;
Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 16 to Week 52:&#xD;
Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 16 to Week 52:&#xD;
Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.&#xD;
Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 16 to Week 52:&#xD;
Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 16 to Week 52:&#xD;
Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label treatment - Tralokinumab + optional TCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 16 to Week 52:&#xD;
Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.&#xD;
OR&#xD;
Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.&#xD;
*TCS = topical corticosteroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label short-term- Tralokinumab + optional TCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 52 to Week 68 [Short term extension (Japan only)] :&#xD;
Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration</description>
    <arm_group_label>Initial treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q4W</arm_group_label>
    <arm_group_label>Open-label short-term- Tralokinumab + optional TCS</arm_group_label>
    <arm_group_label>Open-label treatment - Tralokinumab + optional TCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains the same excipients, in the same concentration only lacking tralokinumab</description>
    <arm_group_label>Initial treatment period - Placebo Q2W</arm_group_label>
    <arm_group_label>Maintenance treatment period - Placebo</arm_group_label>
    <arm_group_label>Maintenance treatment period - Placebo Q2W</arm_group_label>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 and above&#xD;
&#xD;
          -  Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.&#xD;
&#xD;
          -  Diagnosis of AD for ‚â•1 year.&#xD;
&#xD;
          -  Subjects who have a recent history of inadequate response to treatment with topical&#xD;
             medications or for whom topical treatments are otherwise medically inadvisable.&#xD;
&#xD;
          -  AD involvement of ‚â•10% body surface area at screening and baseline.&#xD;
&#xD;
          -  Subjects must have applied a stable dose of emollient twice daily (or more, as needed)&#xD;
             for at least 14 days before randomisation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active dermatologic conditions that may confound the diagnosis of AD.&#xD;
&#xD;
          -  Use of tanning beds or phototherapy within 6 weeks prior to randomisation.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic&#xD;
             corticosteroid within 4 weeks prior to randomisation.&#xD;
&#xD;
          -  Treatment with topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI)&#xD;
             within 2 weeks prior to randomisation.&#xD;
&#xD;
          -  Active skin infection within 1 week prior to randomisation.&#xD;
&#xD;
          -  Clinically significant infection within 4 weeks prior to randomisation.&#xD;
&#xD;
          -  A helminth parasitic infection within 6 months prior to the date informed consent is&#xD;
             obtained.&#xD;
&#xD;
          -  History of anaphylaxis following any biologic therapy.&#xD;
&#xD;
          -  Tuberculosis requiring treatment within the 12 months prior to screening.&#xD;
&#xD;
          -  Known primary immunodeficiency disorder.&#xD;
&#xD;
          -  Alanine aminotransferase or aspartate aminotransferase level ‚â•2.0 times the upper&#xD;
             limit of normal at screening.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core&#xD;
             antibody or hepatitis C virus antibody serology at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Wollenberg, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology and Allergy, Ludwig-Maximilian University Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tien Q. Nguyen, MD, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Dermatology Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists, Inc.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The GWU Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, Inc.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC Dermatology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Pollens Clinical Research Centers, Inc.</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Center at Brookstone Research</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Surgery Specialists</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Christie Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Sciences, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of SWLA, LLC</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermAssociates, PC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSearch LLC</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JDR Dermatology Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo Department of Dermatology</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juva Skin &amp; Laser Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deramatology Consulting Services, PLLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologists of Greater Columbus</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Department of Dermatology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Dermatology Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermtology Treatment and Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Skin Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia Research Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valence</name>
      <address>
        <city>Valence</city>
        <state>Dr√¥me</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital St ANDRE, CHU de BORDEAUX, Service de Dermatologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - H√¥pital Morvan, Service de Dermatologie</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon, Service de Dermatologie</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital Saint vincent de paul, Clinique de Dermatologie</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital Claude Huriez-CHRU, Service de dermatologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet M√©dical, Le Bateau Blanc-Immeuble A</name>
      <address>
        <city>Martigues</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHRMSA, Service de Dermatologie</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire, Clinique dermatologique 7 eme nord</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital de l'Archet II, Service de Dermatologie- V√©n√©rologie</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital Robert Debr√©, Service de Dermatologie</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H√¥pital Charles Nicolle, Clinique Dermatologique</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Saint-Etienne - H√¥pital Nord, Service de dermatologie</name>
      <address>
        <city>Saint-Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse H√¥pital Larrey, Service de Dermatologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma-Study-Center Friedrichshafen GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <state>Baden-W√ºrttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, Klinik f√ºr Dermatologie und Allergologie</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Erlangen, Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU M√ºnchen, Klinik und Poliklinik f√ºr Dermatologie und Allergologie</name>
      <address>
        <city>M√ºnchen</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztpraxis f√ºr Dermatologie, Allergologie, Venerologie und Umweltmedizin</name>
      <address>
        <city>Mahlow</city>
        <state>Brandenburg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt GmbH, Hautklinik</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haut√§rzte Zentrum Hannover</name>
      <address>
        <city>Hann√∂ver</city>
        <state>Lower Saxony</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik f√ºr Dermatologie, Allergologie und Venerologie</name>
      <address>
        <city>Hann√∂ver</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KliFOs - Klinische Forschung Osnabr√ºck</name>
      <address>
        <city>Osnabr√ºck</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld Rosenh√∂he, Hautklinik</name>
      <address>
        <city>Bielefeld</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niesmann, Hautzentrum im Jahrhunderthaus</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Bonn, Klinik und Poliklinik f√ºr Dermatologie und Allergologie</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum D√ºlmen</name>
      <address>
        <city>D√ºlmen</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Essen (A√∂R), Klinik f√ºr Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum M√ºnster Klinik und Poliklinik f√ºr Hautkrankheiten M√ºnster, Zentrale Studienkoordination f√ºr innovative Dermatologie</name>
      <address>
        <city>M√ºnster</city>
        <state>NRW</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Halle (Saale), Universit√§tsklinik und Poliklinik f√ºr Dermatologie und Venerologie</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Saxony-Anhalt</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Carl Gustav Carus, Klinik und Poliklinik f√ºr Dermatologie</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Leipzig, Klinik und Poliklinik f√ºr Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera, Klinik f√ºr klinische Studien</name>
      <address>
        <city>Gera</city>
        <state>Thuringia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charit√© - Universit√§tsmedizin Berlin, Klinik f√ºr Dermatologie, Allergologie und Venerologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMB Collegium Medicum Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meiwa Hospital</name>
      <address>
        <city>Hy≈çgo</city>
        <state>Nishinomiya</state>
        <zip>663-8186</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College Of Medicine Hospital</name>
      <address>
        <city>Hy≈çgo</city>
        <state>Nishinomiya</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KUME Clinic</name>
      <address>
        <city>Sakai City</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Tokyo</city>
        <state>Shinagawa</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa City Hospital</name>
      <address>
        <city>Asahikawa</city>
        <zip>070-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JR Sapporo Hospital</name>
      <address>
        <city>Ch≈´≈ç</city>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Kojinkai</name>
      <address>
        <city>Ch≈´≈ç</city>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu-shi</city>
        <zip>315-0974</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Habikono Medical Center</name>
      <address>
        <city>Habikino</city>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University hospital</name>
      <address>
        <city>Hamamatsu</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichinomiya Municipal Hospital</name>
      <address>
        <city>Ichinomiya</city>
        <zip>491-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Prefectural Central Hospital</name>
      <address>
        <city>Morioka</city>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chukyo Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takagi Dermatological Clinic</name>
      <address>
        <city>Obihiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Teishin Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fraternity Memorial Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>130-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogikubo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>167-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shirasaki Dermatology Clinic</name>
      <address>
        <city>T≈çyama</city>
        <zip>933-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gokeikai Osaka Kaisei Hospital</name>
      <address>
        <city>≈åsaka</city>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Hospital</name>
      <address>
        <city>≈åsaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sof√≠a, Servicio Dermatolog√≠a</name>
      <address>
        <city>C√≥rdoba</city>
        <state>Andaluc√≠a</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena, Servicio Dermatolog√≠a</name>
      <address>
        <city>Sevilla</city>
        <state>Andaluc√≠a</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol, Servicio Dermatolog√≠a</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona, Dermatology Department</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau, Servicio Dermatolog√≠a</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar, Servicio Dermatolog√≠a</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica Universitaria de Navarra, Servicio Dermatolog√≠a</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto, Servicio Dermatolog√≠a</name>
      <address>
        <city>Bilbao</city>
        <state>Pa√≠s Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces, Servicio Dermatolog√≠a</name>
      <address>
        <city>Bilbao</city>
        <state>Pa√≠s Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada, Servicio Dermatolog√≠a</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor, Servicio Dermatolog√≠a</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa, Servicio Dermatolog√≠a</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Servicio Dermatolog√≠a</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Polit√©cnico La Fe, Servicio Dermatolog√≠a</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <disposition_first_submitted>August 5, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 29, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 20, 2020</disposition_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03131648/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03131648/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The screening period was 2 to 6 weeks and included 1 or 2 visits. The exact duration depended on the wash-out period defined by the exclusion criteria. If no wash-out or only a 2-week wash-out was required, screening Visits 1 and 2 were combined. Eligibility was assessed at the (first) screening visit and on Day 0 prior to randomisation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Initial Treatment Period - Tralokinumab 300 mg Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
Tralokinumab: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for SC administration&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
        </group>
        <group group_id="P2">
          <title>Initial Treatment Period - Placebo Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
Placebo: Placebo contains the same excipients, in the same concentration, only lacking tralokinumab.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
        </group>
        <group group_id="P3">
          <title>Maintenance Treatment Period - Tralokinumab 300 mg Q2W</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to tralokinumab 300 mg Q2W maintenance dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
        </group>
        <group group_id="P4">
          <title>Maintenance Treatment Period - Tralokinumab 300 mg Q4W</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to tralokinumab 300 mg Q4W maintenance dosing regimen.&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
        </group>
        <group group_id="P5">
          <title>Maintenance Treatment Period - Placebo Q2W</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomised to tralokinumab re-randomised to placebo Q2W dosing regimen.&#xD;
At each visit, each subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
        </group>
        <group group_id="P6">
          <title>Maintenance Treatment Period- Placebo Q2W - Tralokinumab Naive</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to placebo re-assigned to placebo Q2W.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
        </group>
        <group group_id="P7">
          <title>Open-label Treatment -Tralokinumab 300 mg Q2W + Optional TCS</title>
          <description>Week 16 to Week 52:&#xD;
Subjects receiving initial treatment with tralokinumab/placebo Q2W who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) OR Subjects receiving maintenance treatment with tralokinumab 300 mg Q2W/Q4W or placebo Q2W assigned to open-label treatment after Week 16 with tralokinumab 300 mg Q2W regimen + optional TCS if&#xD;
IGA of at least 2 and not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA=0 at Week 16 OR&#xD;
IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e. over 3 consecutive visits) for subjects with IGA=1 at Week 16 OR&#xD;
Not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA&gt;1 at Week 16&#xD;
At each visit, subjects received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg.</description>
        </group>
        <group group_id="P8">
          <title>Open-label Treatment - Tralokinumab 300 mg Q2W + Optional TCS</title>
          <description>Week 52 to Week 66 [Short term extension (Japan only)]:&#xD;
Japanese subjects who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="603"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued IMP before Week 16</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="564"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="446"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="118"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="112"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Week 50</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="78"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="29"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to open-label treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Week 50</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label (Short Term Extension)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Treatment Period - Tralokinumab 300 mg Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
        </group>
        <group group_id="B2">
          <title>Initial Treatment Period - Placebo Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="603"/>
            <count group_id="B2" value="199"/>
            <count group_id="B3" value="802"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="13.7"/>
                    <measurement group_id="B2" value="39.4" spread="15.2"/>
                    <measurement group_id="B3" value="38.8" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-64 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="574"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-84 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=85 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="328"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="548"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="727"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or african american</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American indian or alaska native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native hawaiian or other pacific islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment</title>
          <description>The Investigator's Global Assessment (IGA) is an instrument used in clinical trials to rate the severity of the subject's global atopic dermatitis and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="199"/>
                    <count group_id="B3" value="802"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eczema Area and Severity Index</title>
          <description>The Eczema Area and Severity Index (EASI) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="601"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="798"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="13.7"/>
                    <measurement group_id="B2" value="32.9" spread="13.9"/>
                    <measurement group_id="B3" value="32.4" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scoring Atopic Dermatitis</title>
          <description>The Scoring Atopic Dermatitis (SCORAD) is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating more extensive and/or severe condition.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="601"/>
                    <count group_id="B2" value="197"/>
                    <count group_id="B3" value="798"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.3" spread="13.0"/>
                    <measurement group_id="B2" value="71.7" spread="12.5"/>
                    <measurement group_id="B3" value="70.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dermatology Life Quality Index</title>
          <description>The Dermatology Life Quality Index (DLQI) consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their health-related quality of life (HQoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4-point Likert scale (0 = 'not at all ‚ÅÑnot relevant'; 1 = 'a little'; 2 = 'a lot'; 3 = 'very much'). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor HQoL.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="591"/>
                    <count group_id="B2" value="194"/>
                    <count group_id="B3" value="785"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.8" spread="7.1"/>
                    <measurement group_id="B2" value="17.0" spread="6.6"/>
                    <measurement group_id="B3" value="16.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Worst Daily Pruritus NRS (weekly average)</title>
          <description>Subjects assess their worst itch severity over the past 24 hours using an 11-point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="598"/>
                    <count group_id="B2" value="195"/>
                    <count group_id="B3" value="793"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="1.4"/>
                    <measurement group_id="B2" value="7.7" spread="1.4"/>
                    <measurement group_id="B3" value="7.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body surface area affected by atopic dermatitis (AD)</title>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>percentage affected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="801"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="24.1"/>
                    <measurement group_id="B2" value="54.2" spread="25.6"/>
                    <measurement group_id="B3" value="53.1" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset of atopic dermatitis (AD)</title>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="801"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" lower_limit="1.0" upper_limit="14.0"/>
                    <measurement group_id="B2" value="3.0" lower_limit="0.0" upper_limit="13.0"/>
                    <measurement group_id="B3" value="3.0" lower_limit="0.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of atopic dermatitis (AD)</title>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="603"/>
                    <count group_id="B2" value="198"/>
                    <count group_id="B3" value="801"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="14.5"/>
                    <measurement group_id="B2" value="29.6" spread="15.1"/>
                    <measurement group_id="B3" value="28.3" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16</title>
        <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
        <time_frame>At Week 16</time_frame>
        <population>The full analysis set (FAS: all subjects randomised to initial treatment who were exposed to IMP) was used for the primary analysis; 802 subjects were randomised to initial treatment and 798 received IMP, thus the FAS comprised of 798 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16</title>
          <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
          <population>The full analysis set (FAS: all subjects randomised to initial treatment who were exposed to IMP) was used for the primary analysis; 802 subjects were randomised to initial treatment and 798 received IMP, thus the FAS comprised of 798 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.The null hypothesis of no difference in response rates between tralokinumab and placebo were tested against the 2-sided alternative that there is a difference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Primary endpoints tested sequentially at a 5% significance level.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Primary endpoints tested sequentially at a 5% significance level.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>13.1</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity. The null hypothesis of no difference in response rates between tralokinumab and placebo were tested against the 2-sided alternative that there is a difference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Primary endpoints tested sequentially at a 5% significance level.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Primary endpoints tested sequentially at a 5% significance level.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>17.7</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.</title>
        <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set (FAS). Number of subjects analysed = subjects with baseline pruritus NRS weekly average ‚â•4.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.</title>
          <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
          <population>Full analysis set (FAS). Number of subjects analysed = subjects with baseline pruritus NRS weekly average ‚â•4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="594"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction of Worst Daily Pruritus NRS weekly average ‚â•4 at Week 16 was tested after the sequential testing of IGA 0/1 and EASI75 if these tests showed statistical significance.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'Composite', subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Tested sequentially at a 5% significance level.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>15</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16</title>
        <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16</title>
          <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition.</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.2" spread="0.94"/>
                    <measurement group_id="O2" value="-14.7" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or after initiation of rescue medication were not included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustment using the Holm method.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'hypothetical'. Repeated measurements model on post-baseline data. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change was imputed as 0.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.4</ci_lower_limit>
            <ci_upper_limit>-6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16</title>
        <description>The Dermatology Life Quality Index (DLQI) is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ‚ÅÑnot relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16</title>
          <description>The Dermatology Life Quality Index (DLQI) is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ‚ÅÑnot relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
          <population>Full analysis set.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="0.31"/>
                    <measurement group_id="O2" value="-5.0" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustment using Holm method.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'hypothetical'. Repeated measurements model on post-baseline data. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change was imputed as 0.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16</title>
        <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
        <time_frame>At Week 52</time_frame>
        <population>Maintenance analysis set - Subjects who achieved IGA 0/1 at Week 16 after initial treatment with tralokinumab without use of rescue medication.&#xD;
Subjects who were treated with placebo during initial treatment period (tralokinumab na√Øve arm) and who continued to the maintenance period were not part of the analysis of maintenance endpoints and therefore this arm is not included for outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q2W maintenance dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg Q4W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q4W maintenance dosing regimen.&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to placebo Q2W dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16</title>
          <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
          <population>Maintenance analysis set - Subjects who achieved IGA 0/1 at Week 16 after initial treatment with tralokinumab without use of rescue medication.&#xD;
Subjects who were treated with placebo during initial treatment period (tralokinumab na√Øve arm) and who continued to the maintenance period were not part of the analysis of maintenance endpoints and therefore this arm is not included for outcome measures.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-label treatment were considered non-responders.&#xD;
P value was considered non-significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>This test was not statistically significant and hence next maintenance endpoint in the sequential testing procedure was not evaluated.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>33.7</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>Test not evaluated for significance. Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-label treatment were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.1</ci_lower_limit>
            <ci_upper_limit>18.0</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 52</time_frame>
        <population>Maintenance analysis set: Subjects who achieved EASI75 at Week 16 after inital treatment with tralokinumab without use of rescue medication.&#xD;
Subjects who were treated with placebo during initial treatment period (tralokinumab na√Øve arm) and who continued to the maintenance period were not part of the analysis of maintenance endpoints and therefore this arm is not included for outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q2W maintenance dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg Q4W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomised to tralokinumab 300 mg Q4W maintenance dosing regimen.&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to placebo Q2W dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Maintenance analysis set: Subjects who achieved EASI75 at Week 16 after inital treatment with tralokinumab without use of rescue medication.&#xD;
Subjects who were treated with placebo during initial treatment period (tralokinumab na√Øve arm) and who continued to the maintenance period were not part of the analysis of maintenance endpoints and therefore this arm is not included for outcome measures.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>Test not evaluated for significance. Based on the primary analysis of the primary estimand 'composite'. Subjects who received rescue medication or were transferred to open-label treatment are considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>21.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>42.6</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <p_value_desc>Test not evaluated for significance. Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-label treatment were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>32.0</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency</title>
        <description>Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>The analysis was performed on the safety analysis set. The safety analysis set comprised of participants who received at least 1 dose of IMP during the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency</title>
          <description>Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.</description>
          <population>The analysis was performed on the safety analysis set. The safety analysis set comprised of participants who received at least 1 dose of IMP during the trial.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="602"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Anti-drug Antibodies</title>
        <description>Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>All subjects in the safety analysis set are included</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Anti-drug Antibodies</title>
          <description>Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method.</description>
          <population>All subjects in the safety analysis set are included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="602"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-existing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perishing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No post-baseline anti-drug antibody assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.3</ci_lower_limit>
            <ci_upper_limit>26.8</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.4</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" lower_limit="-16.6" upper_limit="-14.4"/>
                    <measurement group_id="O2" value="-9.0" lower_limit="-11.1" upper_limit="-7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change will be imputed as 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>-4.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16</title>
        <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with a higher values indicating a more extensive and/or severe condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16</title>
          <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with a higher values indicating a more extensive and/or severe condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication prior to Week 16 or with missing data at Week 16 were considered nonresponders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16</title>
        <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16</title>
          <description>The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis lesions, along with subjective symptoms. The score ranges from 0 to 103, with higher values indicating a more extensive and/or severe condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication prior to Week 16 or with missing data at Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.6</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference stratified by region and disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average)</title>
        <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average)</title>
          <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="598"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-2.8" upper_limit="-2.4"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-2.1" upper_limit="-1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included. In case of no post-baseline assessments before initiation of rescue medication, the Week 1 change will be imputed as 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Worst Daily Pruritus NRS (Weekly Average) ‚â•3 From Baseline to Week 16</title>
        <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set. Number of subjects analysed = subjects with baseline Pruritus NRS weekly average of at least 3</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Worst Daily Pruritus NRS (Weekly Average) ‚â•3 From Baseline to Week 16</title>
          <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
          <population>Full analysis set. Number of subjects analysed = subjects with baseline Pruritus NRS weekly average of at least 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ‚â•4 Points Among Subjects With Baseline DLQI ‚â•4</title>
        <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set. Number of subjects analysed = subjects with baseline DLQI ‚â•4.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W.&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ‚â•4 Points Among Subjects With Baseline DLQI ‚â•4</title>
          <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
          <population>Full analysis set. Number of subjects analysed = subjects with baseline DLQI ‚â•4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="578"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.4</ci_lower_limit>
            <ci_upper_limit>20.5</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initial Treatment Period: Week 0 to Week 16, Maintenance Treatment Period: Week 16 to Week 52, Open-label Treatment: Week 16 to Week 52; Safety Follow-up Period: Week 52 to Week 66 and Week 68 to Week 82 (for selected Japanese subjects).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Initial Period - Tralokinumab Q2W</title>
          <description>Initial Period - Tralokinumab Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab.</description>
        </group>
        <group group_id="E2">
          <title>Initial Period - Placebo</title>
          <description>Initial Period - Placebo&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo.</description>
        </group>
        <group group_id="E3">
          <title>Maintenance Period - Tralokinumab Q2W</title>
          <description>Maintenance Period - Tralokinumab Q2W&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q2W maintenance dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
        </group>
        <group group_id="E4">
          <title>Maintenance Period - Tralokinumab Q4W</title>
          <description>Maintenance Period - Tralokinumab Q4W&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q4W maintenance dosing regimen.&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
        </group>
        <group group_id="E5">
          <title>Maintenance Period - Placebo</title>
          <description>Maintenance Period - Placebo&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to placebo Q2W dosing regimen.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
        </group>
        <group group_id="E6">
          <title>Maintenance Period - Placebo - Tralokinumab Naive</title>
          <description>Maintenance Period - Placebo - Tralokinumab Naive&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to placebo re-assigned to placebo Q2W.&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
        </group>
        <group group_id="E7">
          <title>Open-label Period - Tralokinumab Q2W + Optional TCS</title>
          <description>Open-label Period - Tralokinumab Q2W + Optional TCS&#xD;
Subjects receiving initial treatment with tralokinumab/placebo Q2W who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) OR Subjects receiving maintenance treatment with tralokinumab 300 mg Q2W/Q4W or placebo Q2W assigned to open-label treatment after Week 16 with tralokinumab 300 mg Q2W regimen + optional TCS if IGA of at least 2 and not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA=0 at Week 16 OR IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e. over 3 consecutive visits) for subjects with IGA=1 at Week 16 OR Not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA&gt;1 at Week 16 At each visit, subjects received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg.</description>
        </group>
        <group group_id="E8">
          <title>Safety Follow-up</title>
          <description>Subjects who spent any amount of time in the safety follow-up period, independently of the treatment(s) received before. No treatment was administered to the subjects during the safety follow-up period. Eligible participants who completed treatment could transfer to an open-label long-term extension trial (conducted under a separate protocol) at any any time during the safety follow-up period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="563"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accessory cardiac pathway</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Keratitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Leishmaniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="351" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="76"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="304" subjects_at_risk="563"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="602"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="14" subjects_affected="13" subjects_at_risk="563"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="47" subjects_affected="24" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="13" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" events="21" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="60" subjects_affected="28" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="602"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" events="15" subjects_affected="14" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="602"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="52" subjects_affected="41" subjects_at_risk="563"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="602"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="563"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="602"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="172" subjects_affected="139" subjects_at_risk="602"/>
                <counts group_id="E2" events="54" subjects_affected="41" subjects_at_risk="196"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="68"/>
                <counts group_id="E4" events="26" subjects_affected="18" subjects_at_risk="76"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" events="201" subjects_affected="143" subjects_at_risk="563"/>
                <counts group_id="E8" events="12" subjects_affected="12" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrong patient received medication</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="602"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" events="19" subjects_affected="18" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="50" subjects_affected="28" subjects_at_risk="602"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="29" subjects_affected="22" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="563"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="602"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="198" subjects_affected="152" subjects_at_risk="602"/>
                <counts group_id="E2" events="123" subjects_affected="75" subjects_at_risk="196"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" events="22" subjects_affected="14" subjects_at_risk="76"/>
                <counts group_id="E5" events="18" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E7" events="201" subjects_affected="123" subjects_at_risk="563"/>
                <counts group_id="E8" events="12" subjects_affected="10" subjects_at_risk="595"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="41" subjects_affected="32" subjects_at_risk="602"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" events="27" subjects_affected="20" subjects_at_risk="563"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="595"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Disclosure</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

